All too-often, oral cancer is detected in the late stages. This can make treatment difficult, and heavily impact patients' quality of life. When detected in stages I and II, the chances of survival are doubled.

As such, routine screening for oral cancer is essential and the BeVigilant OraFusion System from Vigilant Biosciences produces a simple and accurate risk assessment to aid in early detection.

figure 1

The non-invasive tool analyses saliva and, in 15 minutes or fewer, produces a report of either low, moderate, or elevated risk levels associated with oral cancer, to assist dentists in their decision making.

For more information about what could be a truly life-changing, pre-diagnostic test, contact the team at Vigilant Biosciences for a demo. For more information, visit www.vigilantbiosciences.com or email info@vigilantbiosciences.com.